Position in ANAB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,127,435
+$1,456,985 QoQ
Shares Held
75,962
-23.5% QoQ
Ownership
0.261%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#49
of 211 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 90%
Shared 0%
None 10%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Granahan Investment Management, LLC holds $227,093,647 across 25 Biotechnology names. ANAB ranks #19 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
147,231 | $46,538,246 | |
| 2 | CELC |
Celcuity Inc.
|
179,053 | $18,732,524 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
461,608 | $15,103,813 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
446,988 | $9,771,157 | |
| 5 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
83,270 | $9,245,468 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
163,759 | $9,006,745 | |
| 7 | TSHA |
Taysha Gene Therapies, Inc.
|
1,305,177 | $8,888,255 | |
| 8 | ZYME |
Zymeworks Inc.
|
336,157 | $8,787,143 |
All Filings in ANAB
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,127,435 | 75,962 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,670,450 | 66,182 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $6,101,450 | 125,855 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $4,524,801 | 147,773 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,922,741 | 131,655 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,723,260 | 146,491 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,404,491 | 106,079 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||